ERBB2 and breast cancer: This universal predominance of luminal (ER- or PR-positive or both and HER2-negative) breast cancer, regardless of race, may be reassuring since this subtype has the best survival [5,17], can be targeted by existing chemoprevention agents [30,31], and may be most readily detectable by screening mammography [9,10,36,37].